Myra Vision, founded with the mission to revolutionize glaucoma treatment, focuses on providing innovative solutions for patients with moderate to severe glaucoma. The company aims to deliver personalized intraocular pressure (IOP) control, addressing the evolving needs of patients while ensuring safety without compromising efficacy. Myra Vision's core product is designed to offer maximum IOP reduction, filling significant gaps in current treatment options and improving patient outcomes.

Notable affiliated individuals and investors have not been disclosed publicly. However, Myra Vision has made significant strides in the medical field, as evidenced by their recent announcements and advancements. The company's approach, which emphasizes predictable outcomes through an established delivery technique, has positioned it as a pioneering force in glaucoma treatment. Myra Vision's impact is marked by its commitment to enhancing the quality of life for glaucoma patients through cutting-edge medical innovation.